21 CFR § 862.1163 Clinical Chemistry and Clinical Toxicology Devices

§ 862.1163 Cardiac allograft gene expression profiling test system.

Current through Sep 8, 2026 · Read all of Part 862

⚠ 2 pending changes to Part 862

(a) Identification. A cardiac allograft gene expression profiling test system is a device that measures the ribonucleic acid (RNA) expression level of multiple genes and combines this information to yield a signature (pattern, classifier, index, score) to aid in the identification of a low probability of acute cellular rejection (ACR) in heart transplant recipients with stable allograft function.

(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Cardiac Allograft Gene Expression Profiling Test Systems.” See § 862.1(d) for the availability of this guidance document.

[74 FR 53885, Oct. 21, 2009]

← § 862.1160 Bicarbonate/carbon dioxide test system.§ 862.1164 Setmelanotide eligibility gene variant detection system. →